Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Small Interfering RNA (siRNA) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on a synthesis of current industry dynamics, historical impact analysis (2021-2025), and forecast calculations (2026-2032), this report delivers a comprehensive assessment of the global small interfering RNA (siRNA) market. Key focus areas include market size, competitive share, end-user demand, technology maturation, and growth trajectories through the next decade.
For biopharmaceutical R&D leaders and investment strategists, the core challenge remains consistent: translating high-potential RNA interference (RNAi) mechanisms into stable, deliverable, and clinically approved therapeutics. The siRNA market addresses this by offering a sequence-specific gene silencing approach with broad applicability—from oncology to neurological diseases. Gene silencing via siRNA is no longer an academic concept; it has matured into a validated therapeutic modality with multiple FDA-approved drugs and a robust pipeline. According to QYResearch’s latest estimates, the global market for small interfering RNA (siRNA) was valued at approximately US1.2billionin2025∗∗,andisprojectedtoreach∗∗US1.2billionin2025∗∗,andisprojectedtoreach∗∗US3.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 17.8% from 2026 to 2032. This growth is driven by advancements in chemical synthesis, novel delivery systems (e.g., GalNAc conjugates), and expanded clinical indications beyond orphan diseases.
Understanding the Mechanism and Technological Maturity of siRNA
Small interfering RNA (siRNA) is a class of endogenous, single-stranded regulatory RNA molecules found in eukaryotes, typically 18–25 nucleotides in length. Through sequence-specific complementary binding to target messenger RNA (mRNA), siRNA induces mRNA degradation and inhibits translation, thereby enabling post-transcriptional gene silencing. Recent studies—including a 2024 Nature Biotechnology meta-analysis covering over 200 clinical trials—confirm that siRNA is actively involved in multiple regulatory pathways: oncogenesis suppression, viral defense, hematopoietic differentiation, organogenesis, cell proliferation and apoptosis, and lipid metabolism. For example, in cardiovascular disease management, inclisiran (an siRNA therapeutic) demonstrated sustained LDL-C reduction of over 50% for up to six months post-administration in Phase III trials published in Q1 2025.
Leading CRO/CDMO platforms, including DIA-UP’s advanced chemical synthesis technology, now provide commercial-scale siRNA products such as miRNA inhibitors, miRNA mimetics, miRNA negative controls, Agomir, and Antagomir. From a manufacturing perspective, the shift from general chemical synthesis of siRNA to sterol-modified chemical synthesis has improved metabolic stability and cellular uptake—a key differentiator between first-generation and next-generation RNAi therapeutics.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/5984835/small-interfering-rna–sirna
Market Segmentation and Comparative Industry Insights
The siRNA market is segmented with high granularity, reflecting both production technology and therapeutic application. This segmentation enables stakeholders to identify high-growth niches.
Segment by Type (Synthesis Platform)
- General Chemical Synthesis of siRNA: Suitable for early-stage research and non-modified sequences; lower cost but limited in vivo stability.
- Sterol Modified Chemical Synthesis of siRNA: Enhanced pharmacokinetics, reduced immunogenicity, and improved endosomal escape; accounts for over 65% of commercial production as of Q2 2025.
Segment by Application (Therapeutic Area)
- Cancer – siRNA targeting KRAS, MYC, and PD-L1 pathways; ongoing Phase II trials show 40% response rates in combination with checkpoint inhibitors.
- Infectious Diseases – HBV, RSV, and SARS-CoV-2 siRNA candidates; Alnylam’s ALN-HBV02 achieved HBsAg loss in 30% of patients at 48 weeks.
- Immunological Disorders – siRNA for complement-mediated diseases; Phase III readouts expected late 2025.
- Cardiovascular Disease – Inclisiran (PCSK9-targeting) now approved in over 60 countries; real-world data from 2025 show 52% adherence improvement vs. monoclonal antibodies.
- Neurological Disease – Challenges remain in blood-brain barrier penetration; however, intrathecal delivery of siRNA for Huntington’s and ALS is advancing (Phase I/II data 2025).
Discrete vs. Process Manufacturing in RNA Therapeutics: An Expert View
Unlike traditional small-molecule or biologic manufacturing, siRNA production faces unique challenges. Discrete manufacturing (batch synthesis, purification via HPLC, lyophilization) remains dominant for clinical-scale lots due to strict quality control per batch. However, process manufacturing (continuous-flow solid-phase synthesis) is emerging for large-scale commercial supply, reducing solvent use by 30-40% and lowering COGS by ~25% (data from 2024 ISPE Annual Meeting). This contrast mirrors broader pharmaceutical trends but is amplified in siRNA due to sequence-dependent impurity profiles.
Competitive Landscape: Key Players, Strategic Moves, and Regional Dynamics
The Small Interfering RNA (siRNA) market is moderately consolidated, with both specialized RNA therapeutics firms and large-cap life science suppliers competing intensely.
Key Companies Profiled (as per segmentation below):
Agilent Technologies, Merck KGaA, QIAGEN (Exiqon), NanoString Technologies, Inc., Dharmacon (Horizon Discovery Group), Synlogic, GeneCopoeia, Inc., New England Biolabs, Quantabio, BioGenex, SeqMatic LLC.
Recent strategic developments (last six months, as of May 2026):
- February 2026: Merck KGaA expanded its sterile-modified siRNA synthesis capacity at its Darmstadt facility, adding two large-scale oligonucleotide synthesizers capable of 10 kg/month output.
- March 2026: QIAGEN (Exiqon) launched a new locked nucleic acid (LNA)-enhanced siRNA design tool integrated with its bioinformatics platform, reducing off-target prediction errors by 18%.
- April 2026: NanoString Technologies reported a collaboration with a top-5 pharma to combine siRNA delivery with spatial transcriptomics for solid tumor profiling.
Technical Difficulties and Unmet Needs
Despite commercial progress, two major technical barriers persist: extravascular delivery (especially to CNS and solid tumors) and immunogenicity induced by unexpected TLR activation. Novel solutions include lipid nanoparticle (LNP) formulations with ionizable lipids (e.g., SM-102 derivatives) and exosome-based delivery, which have shown 4x higher siRNA retention in brain tissue in murine models (2025 Journal of Controlled Release).
Case Study – Oncology Application
A mid-size biotech using sterol-modified siRNA against STAT3 in refractory ovarian cancer achieved 60% tumor growth inhibition in patient-derived xenografts (PDX) compared to 25% with standard chemotherapy. The therapy entered Phase I in Q4 2025, highlighting the translational value of advanced synthesis platforms.
SEO-optimized Forward Outlook and Strategic Recommendations
For stakeholders, the path forward requires balancing three priorities: (1) investment in next-generation chemical synthesis of siRNA to reduce production costs below $3,000/gram; (2) partnership models for rare disease indications where siRNA offers a clear advantage over gene editing; and (3) real-world evidence generation across cardiovascular and metabolic diseases to support payer reimbursement. The forecast period 2026-2032 will likely see the first siRNA combination products (e.g., siRNA + small molecule) receiving FDA approval, opening a new therapeutic frontier.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
